EUCTR2015-003816-19-LV进行中（未招募）1 期
A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due toAge-Related Macular Degeneration
ForSight VISION4, Inc0 个研究点目标入组 30 人开始时间: 2016年6月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Males and females 50 years of age or older
- •2.Capable of understanding the requirements of the study, willing to follow study instructions, to provide written informed consent to participate, and who agree to comply with all study requirements, including the required study follow-up visits.
- •3.Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography for which anti-VEGF intraocular injection is indicated (> 25% active disease with < 75% of the lesion size representing scar, pigment epithelial detachment, blood or atrophy).
- •4.Intravitreal treatment of study eye with VEGF-inhibitor(s) ranibizumab, bevacizumab, or Eyelea (aflibercept) within the past 12 months, with demonstrated response (decrease in central subfield foveal thickness (CSFT) of 50 µm or greater from prior measurement).
- •5.Increased retinal thickness defined as central subfield foveal thickness (CSFT) in excess of + 2 standard deviations of normal (315 microns as measured by Spectralis OCT).
- •6.CSFT must measure 50 µm greater than the lowest CSFT following the anti-VEGF injection to which responsiveness had been confirmed within the preceding 6 months.
- •7.Best corrected visual acuity between 20/80 and counting fingers in the eye to be treated
- •8.Best corrected visual acuity in fellow eye = study eye
- •9.Sufficient media clarity to allow for good visibility of macular area on biomicroscopy
- •If both eyes of an individual qualify, the eye with the worse BCVA will be selected as the study eye. If both eyes have the same BCVA, the study eye will be the eye with the worse macular edema.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1.Prior vitrectomy in the study eye
- •2.Any periocular/intraocular injections in the study eye in the past 2 months.
- •3.Any ophthalmic surgery performed on the study eye within the past 1 month
- •4.Recent or current evidence of ocular infection or inflammation in either eye.
- •5.Use of anticoagulant, non-inclusive of non-steroidal anti-inflammatory agents (NSAID) or aspirin, within 14 days of enrollment
- •6.Uncontrolled glaucoma defined as IOP greater than 25 mm Hg.
- •7.Hypotony (defined as IOP of 5 mm Hg or less)
- •8.Uncontrolled hypertension, systolic BP > 155 mm Hg.
- •9.Uncontrolled systemic disease (eg, diabetes, hypertension, etc.) that in the opinion of the Investigator could confound the study outcomes or prevent the patient from completing the study
- •10.Participation in any study involving an investigational drug within the past 30 calendar days, or ongoing participation in a study with an investigational product.
- •11.Known intolerance or hypersensitivity to any component of the investigational drug or ranibizumab formulations to be used (eg, polyvinylpyrrolidone [PVP], cyclodextrins), components of the drug delivery device (polymethyl methacrylate [PMMA], titanium, silicone), or to topical anesthetics, mydriatics or antibiotics.
- •12.Females who are pregnant or nursing and women of childbearing potential who are not using adequate contraceptive precautions (eg, intrauterine device, oral contraceptives, barrier method or other contraception deemed adequate by the Investigator)
- •13.Have angioid streaks, presumed ocular hisoplasmosis syndrome, myopia (> 8 diopters) or CNV secondary to other causes than AMD
- •14.Any additional ocular disease, which may have irreversibly compromised visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, or diabetic retinopathy
- •15.Inability to obtain photographs, fluorescein angiography (FA) or OCT to document CNV, eg, due to media opacity, allergy to fluorescein dye or lack of venous access
- •16.Any condition that, in the opinion of the investigator, would jeopardize the safety of the subject
研究者
相似试验
已完成
1 期
DCB-DM101 in Participants with Type 2 Diabetes MellitusType 2 Diabetes MellitusACTRN12618001140246VitNovo Australia Pty Ltd24
尚未招募
1 期
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis.Myeloproliferative Neoplasms (MPN)Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)Essential Thrombocythemia (ET)Cancer - ThrombocythaemiaCancer - BoneCancer - Leukaemia - Chronic leukaemiaBlood - Haematological diseasesACTRN12624000478516Jubilant Therapeutics, Inc.30
招募中
1 期
A Phase I Study to Evaluate the Safety and Efficacy of Mesenchymal Stromal Cells (MSC) for Treating Chronic Obstructive Pulmonary Disease (COPD)COPDRespiratory - Chronic obstructive pulmonary diseaseACTRN12614000731695Royal Perth Hospital10
招募中
1 期
Safety and Efficacy of MagSense Human Epidermal Growth Factor Receptor 2 (HER2) Test Reagent in Breast Cancer Lymph Node Magnetic Reasonance Imaging (MRI) and Magnetic Relaxometry (MRX).Cancer - BreastBreast CancerACTRN12621000126819Imagion Biosystems, Ltd30
已完成
2 期
A Pilot Study to Evaluate the Safety and Efficacy of Rituximab in Combination with Out-Patient Based Vinorelbine, Gemcitabine and Pegfilgrastim (VGF)/Pegfilgrastim, Gemcitabine, Ifosfamide and Vinorelbine (F-GIV) Salvage Therapies in the treatment of Relapsed/Refractory CD20+ Lymphomas.Relapsed and refractory CD20+ lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphomaACTRN12606000386538Associate Professor Andrew Spencer12